| Bioactivity | Eloralintide (LY 3841136) is an AMYR agonist, which is promising for research of type 2 diabetes and obesity[1]. |
| CAS | 2883634-40-8 |
| Sequence | {γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7) |
| Shortening | {γGlu}-CNTATCATG-{Orn}-LAE-{(α-Me-Phe)}-LVRSSN-{(N-Me-Asn)}-FGP-{Lys(γGlu-γGlu-C20 diacid)}-LPPTEVGSNTY-NH2 (Methylene bridge: Cys2-Cys7) |
| Formula | C201H319N49O65S2 |
| Molar Mass | 4526.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. |
Eloralintide
CAS: 2883634-40-8 F: C201H319N49O65S2 W: 4526.10
Eloralintide (LY 3841136) is an AMYR agonist, which is promising for research of type 2 diabetes and obesity.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.